Allergy patients are being warned about the risk of adrenaline pen failure.
Bausch & Lomb UK limited has informed The Medicines and Healthcare products Regulatory Agency (MHRA) of a risk that Emerade adrenaline pens could fail to deliver a dose of adrenaline from the syringe due to blockage of the needle.
This notification applies to Emerade devices of all strengths. It does not apply to the other marketed brands of adrenaline auto-injectors.
The potential for units on the market to have a blockage of the needle which could lead to Emerade pen failing to deliver a dose when activated is now estimated to be 2.3 in every thousand pens.
Patients are urged to follow the existing advice and carry two in-date pens with them at all times, the risk of not being able to deliver a dose of adrenaline before the emergency services arrive is substantially reduced (from 0.23% to 0.000529%).
Anaphylaxis training and advice emphasises that two pens are recommended to be carried at all times in case the patient does not improve after the first injection which may occur for a number of reasons.
Anaphylaxis is included in the range of First Aid Training Courses that Essential 6 deliver at sites in Devon and across the UK. For training and support please contact us.
Further details are available here